Furthermore, lower use of potent antiplatelet therapy (both preprocedural P2Y12 loading dose and per-procedure glycoprotein IIb/IIIa inhibitors), IVUS, and postdilation could be important factors associated with the higher incidence of target vessel–related MI in the European cohort.13 Here, P2RY12 is linked to myocardial infarction.